Four species of the genus Ebolavirus cause severe and often lethal disease in humans:
Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Taï Forest ebolavirus (TAFV) …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell
entry and the focus for development of protective antibodies and vaccines. Structural studies …

Unique gut microbiota compositions have been associated with inflammatory diseases, but
identifying gut bacterial functions linked to immune activation in humans remains …

Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and
therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for …

The SARS-CoV-2 pandemic has unprecedented implications for public health, social life,
and the world economy. Because approved drugs and vaccines are limited or not available …

Ebola virus disease causes widespread and highly fatal epidemics in human populations.
Today, there is still great need for point-of-care tests for diagnosis, patient management and …

Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …

Ebola viruses (EBOVs) are responsible for repeated outbreaks of fatal infections, including
the recent deadly epidemic in West Africa. There are currently no approved therapeutic …